Register for free to
view the full innovation profile.
This technology has the potential to be used as combination therapeutics for breast cancer treatments.
About
Description Novel Hsp90 Inhibitors for Breast Cancer Treatment Advantage of Invention Researchers at GRU discovered that beauvericin and its certain derivatives are very effective inhibitors of Hsp90 and the inhibition does not generate heat shock responses (i.e. do not overexpress Hsp70 and Hsp27). This technology has the potential to be used as combination therapeutics for breast cancer treatments.